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Herpes simplex virus (HSV) recombinants induce durable immune responses in rhesus macaques and mice and have induced partial protection
in rhesus macaques against mucosal challenge with virulent simian immunodeficiency virus (SIV). In this study, we evaluated the properties of a
new generation HSV vaccine vector, an HSV-1 multiple immediate-early (IE) gene deletion mutant virus, d106, which contains deletions in the
ICP4, ICP27, ICP22, and ICP47 genes. Because several of the HSV IE genes have been implicated in immune evasion, inactivation of the genes
encoding these proteins was expected to result in enhanced immunogenicity. The d106 virus expresses few HSV gene products and shows
minimal cytopathic effect in cultured cells. When d106 was inoculated into mice, viral DNA accumulated at high levels in draining lymph nodes,
consistent with an ability to transduce dendritic cells and activate their maturation and movement to lymph nodes. A d106 recombinant expressing
Escherichia coli β-galactosidase induced durable β-gal-specific IgG and CD8+ T cell responses in naive and HSV-immune mice. Finally, d106-
based recombinants have been constructed that express simian immunodeficiency virus (SIV) gag, env, or a rev-tat-nef fusion protein for several
days in cultured cells. Thus, d106 shows many of the properties desirable in a vaccine vector: limited expression of HSV gene products and
cytopathogenicity, high level expression of transgenes, ability to induce durable immune responses, and an ability to transduce dendritic cells and
induce their maturation and migration to lymph nodes.
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Viral recombinant strains expressing heterologous proteins
have been tested widely as vaccine vectors against a number of
virus infections (Murphy and Chanock, 2001), and a number of
viruses, including pox viruses, adenoviruses, parvoviruses,
alpha viruses, and herpes viruses have been utilized. Despite the⁎ Corresponding author. Fax: +1 617 432 0223.
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vaccines, none have been very effective against the pathogenic
simian immunodeficiency virus (SIV) strains in nonhuman
primates in the infection models that most closely approximate
human immunodeficiency virus (HIV) infection of humans.
Thus, there is a continuing dire need to design and test novel
vaccine approaches as candidate AIDS vaccines.
We have previously used herpes simplex virus 1 recombi-
nants as vaccine vectors expressing SIV envelope protein and
have shown that these recombinants could induce partial
protection against mucosal SIVmac239 infection in rhesus
macaques (Murphy et al., 2000). One of these vectors, HSV-1
d27, was a replication-defective mutant strain that was defective
for the UL54 (ICP27) gene. In this study, we have attempted to
187D. Watanabe et al. / Virology 357 (2007) 186–198improve upon that first-generation vaccine vector by the use of
recombinant HSV-1 strains that contain additional mutations
beyond the ICP27 gene mutation.
Herpes simplex virus productive infection involves the
expression of a series of kinetically regulated groups of viral
genes (Roizman and Knipe, 2001). Viral immediate-early (IE)
genes are transcribed immediately upon viral entry without
prior viral protein synthesis. Three of the IE proteins, ICP4,
ICP0, and ICP27, stimulate later viral gene expression. The next
set of genes expressed, the early genes, encode viral proteins
mostly involved in viral DNA replication. Following viral DNA
replication, the late viral genes are expressed optimally. HSV
infection shuts down host transcription, RNA splicing, and
protein synthesis. Inhibition of host cell protein synthesis
requires both the virion host shutoff (vhs) function and the IE
ICP27 protein (Smiley, 2004; Song et al., 2001). Inhibition of
host transcription requires both ICP4 and ICP27 (Spencer et al.,
1997) whereas inhibition of RNA splicing requires ICP27
(Hardy and Sandri-Goldin, 1994).
HSV recombinants have a number of properties that would be
advantageous for a vaccine vector. HSV can infect a wide range
of tissues and host species and can generate immune responses by
various routes of inoculation, including mucosal (intranasal or
intravaginal) administration. HSV induces durable immune
responses, in part due to latent infection and reactivation, but
replication-defective mutant HSV strains induce equally durable
immune responses (Morrison and Knipe, 1994). Herpesviral
recombinants can accommodate sizeable inserts of heterologous
DNA for vectoring purposes (Knipe et al., 1978) and induce Th1-
biased cellular responses (Brubaker et al., 1996; Nguyen et al.,
1994), which are desirable properties for a vaccine vector. HSV-1
activates TLR2 (Kurt-Jones et al., 2004, 2005) to induce a pro-
inflammatory cytokines as well as activating TLR9 to induce
type I interferons (Krug et al., 2004; Lund et al., 2003). Also, an
HSV replication-defective vector expressing β-galactosidase
showed full immunogenicity in the presence of pre-existing
anti-HSV immunity (Brockman and Knipe, 2002).
However, HSV recombinants express a large number of HSV
proteins that could either evade or blunt the host immune
response or compete for immunogenicity with a vector-
expressed heterologous antigen. Therefore, mutating the ICP4
or ICP27 genes could improve the immunogenicity of the
transgene product by reducing the number of HSV gene
products expressed. Similarly, ICP4 and ICP27 inhibit the
transcription of host genes, and this could decrease antigenic
presentation by down-regulating MHC class I in infected cells,
for example. HSV ICP47 has been shown to block TAP
transport of peptides into the ER for loading onto MHC class I
(York et al., 1994) whereas ICP22 has been reported to inhibit
MHC class II presentation (Barcy and Corey, 2001). Thus,
mutational inactivation of these genes would be expected to
increase the immunogenicity of a vaccine vector. An additional
approach that addresses these issues is the use of HSVamplicon
or replicon strains (Spaete and Frenkel, 1982) as vaccine
vectors. HSV-1 amplicons expressing HIV envelope are
immunogenic in mice (Gorantla et al., 2005; Hocknell et al.,
2002) but no information is available about immunogenicity inprimates. Production issues may limit this approach using
current technology.
Samaniego et al. (1998) studied the properties of a number of
recombinant HSV-1 strains that are defective for various
permutations of IE genes. A recombinant virus in which all
IE genes were inactivated showed the lowest cytopathic effect
on host cells but very low expression of the GFP transgene. The
d106 recombinant strain, which expresses only one IE protein,
ICP0, showed the highest GFP transgene expression balanced
with less cytopathogenicity than many of the other strains. The
d106 virus contains deletions of the ICP4 and ICP27 ORFs and
contains deletions of the promoter/enhancers of the ICP22 and
ICP47 genes (Samaniego et al., 1998). The d106 virus can be
grown in cell lines that contain the ICP4 and ICP27 genes,
which are activated upon viral infection and complement the
defects in those genes. Expression of ICP4 enhances expression
of ICP22, allowing enhanced growth of the virus in the cells.
Because of the potential for expression of the transgene and
limited cytopathogenicity, we have chosen the d106 strain for
study as a second-generation HSV-1 replication-defective
vaccine vector.
Results
Properties of d106 virus as a vaccine vector
We have previously used an HSV-1 replication-defective
ICP27 (UL54) gene mutant, HSV-1 d27, as a vaccine vector for
expression of SIV proteins and immunization of rhesus
macaques, resulting in protection of some of the monkeys
against mucosal challenge infection with pathogenic SIV
mac239 virus (Murphy et al., 2000). To try to improve upon
the d27 vector, we tested a virus with additional IE gene
mutations, the d106 mutant strain (Samaniego et al., 1998).
HSV-1 d106 (Fig. 1A) contains deletions inactivating four of
the five IE genes (ICP4, ICP27, ICP22, and ICP47) and has an
expression cassette containing the green fluorescent protein
(GFP) gene under the control of the human cytomegalovirus
(HCMV) IE promoter-enhancer inserted into the ICP27 gene
locus as a model transgene (Fig. 1A). ICP4 is the major
transactivator of E and L viral genes; therefore, deletion of the
ICP4 gene would decrease HSV gene expression, reducing
antigenic competition with the transgene products. ICP47 binds
to the TAP peptide transporter and blocks peptide transport into
the endoplasmic reticulum and loading of MHC class I, thereby
blocking MHC class I presentation (York et al., 1994). ICP22
has also been reported to inhibit MHC class II presentation
(Barcy and Corey, 2001); therefore, its lack of expression
should also improve immunogenicity of the vector.
Samaniego et al. (2001) compared a number of HSV-1
strains that were mutated for varying numbers of HSV IE genes.
They found that d106 showed more GFP transgene expression
than other mutant strains. We therefore chose this strain for
testing as a vaccine vector. Because Samaniego et al. (2001) had
observed that d106 infection caused a reduction in colony
formation in infected Vero cells, we first examined the
cytopathic effect and host protein synthesis shutoff induced
Fig. 2. Properties of the multiple IE gene-deleted HSV-1 d106 recombinant. (A)
Comparison of morphological changes between d106- and 8GFP-infected cells
(MOI=1) at 20 h post infection. Phase contrast and fluorescence images are
shown. (B) Analysis of infected cell protein synthesis. Vero cells were infected
at MOI=1 with wild-type HSV strain KOS1.1, d106 or 8GFP. At the indicated
times, cells were pulse-labeled with 35S-methionine for 30 min. Infected-cell
lysates were resolved by SDS–PAGE. (C) Detection of viral DNA in the
draining lymph nodes. BALB/cJ mice were infected by subcutaneous infection
into the right flank with 2×106 PFU of KOS1.1, d106, or 8GFP. At the indicated
times, inguinal lymph nodes were removed and viral DNAwas detected by PCR
in 50 ng of total DNA using primers specific for the VP16 gene.
Fig. 1. Genomic structures of HSV-1 recombinants used in this study. (A)
Genomic maps of d106 and d106-LacZ recombinants. A β-galactosidase
expression cassette was inserted into the UL54 gene by homologous
recombination in the d106-LacZ virus. CMV, promoter/enhancer sequences of
the CMV IE gene; PA, polyadenylation signal. (B) HSV-1 wt strain KOS1.1 and
replication-defective KOS1.1-derived recombinant HD-2 and replication-
competent recombinant 8-GFP. HD-2 encodes a truncated ICP8 protein fused
to E. coli β-galactosidase (β-gal). The 8-GFP virus encodes a full-length ICP8
protein fused to green fluorescent protein (GFP).
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we used a replication-competent HSV-1 strain, 8GFP, which is
derived from HSV-1 strain KOS1.1 and expresses GFP fused to
the viral ICP8 protein (Fig. 1B). HSV-1 vhs and ICP27 are both
required for shutoff of host protein synthesis (Song et al., 2001).
Because of the ICP27 gene defect in d106, we expected that
there would be reduced host shutoff in d106-infected cells.
To study the effects of d106 on its host cells, we infected
Vero cells (MOI=1 PFU/cell) with either d106 or 8GFP. First,
we examined the morphological changes occurring in infected
cells. At 22 h post infection (hpi), cells were fixed and examined
by phase-contrast and fluorescence microscopy (Fig. 2A). GFP
was expressed in cells infected with each of the viruses. Cells
infected with HSV-1 8GFP showed swelling and rounding,
characteristic of the typical morphological changes seen in HSV
infection. The d106-infected Vero cells did not show any
remarkable morphological changes through at least 22 hpi.
Second, we examined host protein synthesis to determine the
effects of d106 virus infection. Vero cells were infected
(MOI=1) with d106, 8GFP, or wt HSV-1. At the times
indicated in Fig. 2B, cells were pulse-labeled with 35S-
methionine for 30 min. After labeling, the cells were lysed in
SDS sample buffer and analyzed by SDS–PAGE. In 8GFP- and
WT virus-infected cell lysates, viral protein synthesis and the
shutoff of host cell protein synthesis were observed. In contrast,
in d106-infected cell lysate, viral gene expression was restricted
in that only ICP0, ICP6 (an early viral protein induced by ICP0)
and GFP were observed. Host protein synthesis was maintained
through at least 12 h following d106 infection (Fig. 2B).HSV-1infection has been shown to inhibit the maturation of dendritic
cells (Salio et al., 1999). Because d106 shows little to no host
shutoff, we expected that d106 would not inhibit dendritic cell
maturation. To determine the effect of d106 on maturation and
lymph node migration of dendritic cells in vivo, we measured
the amount of viral DNA in the draining lymph nodes (LNs) of
Fig. 3. Expression of β-galactosidase in recombinant virus-infected cells. (A)
Vero cells were infected with HD-2 or d106-LacZ and harvested at indicated
times. Proteins were separated by SDS–PAGE and electrophoretically
transferred to PVDF membranes. Western blotting was performed using anti-
β-gal antibody. (B) Measurement of β-gal enzymatic activity. Vero cells were
infected with d106-LacZ or HD-2. At the times indicated, cells were lysed in
reporter lysis buffer and enzymatic activity was measured as described in
Materials and methods.
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subcutaneous (s.c.) infection into the right flank with 2x106
PFU of KOS1.1, 8GFP, or d106. At the indicated times, the
mice were sacrificed, inguinal LNs were removed, and DNA
was extracted. HSV DNAwas detected by PCR amplification of
VP16 gene sequences and agarose gel electrophoresis, using
50 ng of total DNA (Fig. 2C). WT HSV-1 DNAwas detected at
only low levels at 16 hpi but higher amounts of 8GFP and high
amounts of d106 DNAwere detected at that time (Fig. 2C). The
highest amounts of viral DNA were detected in lymph nodes
from d106 virus-infected mice, indicating the ability of this
virus to transduce cells that migrate to the lymph nodes.
Taken together, these experiments showed that d106 has
several properties desired in a vaccine vector: limited cyto-
pathogenicity, high-level expression of transgenes, and the
ability to transduce dendritic cells and induce their maturation.
A d106 recombinant virus expressing β-galactosidase as a
model antigen
To measure immune responses against a model antigen, β-
galactosidase (β-gal), we replaced the GFP expression cassette
in d106 with a lacZ expression cassette to generate the d106-
LacZ virus (Fig. 1A), as described in Materials and methods. To
test for expression of β-gal, Vero cells were infected with either
d106-LacZ or with HD-2 (Fig. 1B), an HSV-1 strain that
expresses β-gal fused to the N-terminal 282 residues of the viral
ICP8 protein (Gao and Knipe, 1989). At the indicated times
(Fig. 3A), infected cells were harvested, and western blotting
was performed with an anti-β-gal antibody. β-Gal was detected
in d106-LacZ-infected Vero cell lysates by at least 6 hpi and
increased until 48 hpi. In contrast, β-gal expression peaked at a
lower level by 12 hpi in cells infected with HD-2 (Fig. 3A).
As an alternative quantitative assay of β-gal expression, we
measured enzymatic activity in infected cell lysates (Fig. 3B).
At 12 hpi, the amount of β-gal activity in d106-LacZ-infected
Vero cells was more than five times greater than that of HD-2-
infected cells, and at 24 h post infection, d106-LacZ-infected
cells still showed high expression of β-gal. These data indicated
that d106-LacZ can express high amounts of β-gal upon
infection of cultured cells.
Immunization with the d106-LacZ virus induced robust and
durable IgG antibody responses in mice
To examine the β-gal-specific immune responses induced by
d106 or other HSV vectors, we immunized mice and examined
humoral and cellular responses. Groups of eight BALB/cJ mice
were inoculated s.c. in the flank with 2×106 PFU of d106-LacZ
or HD-2 virus or mock-infected with uninfected Vero cell
lysate. Booster immunizations were performed at 3 and
6 weeks. Serum samples were collected from the mice at the
indicated times, and β-gal-specific IgG antibody titers were
measured by ELISA. We observed that the β-gal antibody
responses in d106-LacZ-infected mice were several fold higher
than those in HD-2-inoculated mice at early times (Fig. 4A). We
also observed that β-gal-specific antibody responses in d106-LacZ mice plateaued at approximately 12 weeks and were
maintained at that level for at least 40 weeks, approximately
40% higher than titers than those of HD-2 virus-inoculated mice
(Fig. 4B). Therefore, d106 has the ability to generate a durable
IgG response against a transgene product.
Pre-existing anti-HSV immunity does not diminish antibody
responses to HSV vector
We observed previously that preexisting host anti-HSV
immunity does not diminish the efficacy of an HSV replication-
defective virus vector (Brockman and Knipe, 2002). To test if
d106 shared this property, we first infected mice with 2×106
PFU of wild-type HSV-1 or mock-infected mice with Vero cell
lysate at 0 and 3 weeks and then inoculated the mice with
2×106 PFU of d106-LacZ or HD-2 virus at 6, 9, and 12 weeks.
We used cell-free virus stocks of the latter two viruses to reduce
the levels of soluble β-gal protein in the virus stock, which
could induce antibody responses independently of virus
infection. Sera were collected at weeks 3, 6, 9, 12, and 15,
and β-gal-specific IgG antibody titers were measured by
ELISA. Despite the increased level of anti-HSV immunity
Fig. 4. Induction and durability of IgG responses in mice. The induction of IgG antibody specific for β-galactosidase (A) and the durability of the β-gal IgG responses
(B) are shown. Groups of six mice were immunized with 2×106 PFU of d106-LacZ or HD-2 at weeks 0, 3, and 6 (arrows). Serum samples were collected at the
indicated times, and β-gal-specific IgG antibody titers were determined by ELISA. Results are shown as the mean titer (log2)±standard deviation.
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titer=7.75 at week 6, data not shown), HD-2 virus (Fig. 5A)
or the d106-LacZ virus (Fig. 5B) induced β-gal-specific IgG
antibody responses that were equivalent in mock-treated versus
immune animals. The IgG titers induced by d106-LacZ were
more than 4 times greater than those by HD-2 in both naive and
immunized mice. Therefore, d106-LacZ recombinant virus
elicited robust β-gal-specific antibody responses even in mice
having preexisting anti-HSV-1 antibody.
Antibody responses to β-galactosidase were diminished by UV
irradiation of the vector
The results of ELISA assay showed that both infected cell
lysate and supernatant stocks of d106-LacZ induced β-gal-
specific antibody responses in mice. To further confirm that the
β-gal-specific antibody responses that we observed were the
result of vector-expressed antigen, we examined IgG responsesFig. 5. Induction of β-galactosidase IgG after prior HSV-1 infection. Titers of IgG spe
mice were immunized twice, at weeks 0 and 3 (open arrows), with 2×106 PFU of w
2×106 PFU of cell-free HD-2 or d106-LacZ virus (solid arrows). Serum samples we
shown as the mean reciprocal dilution (log2)±standard deviation.in mice immunized with virus in cell lysates and cell
supernatant virus preparations either UV-inactivated or not
treated. UV treatment resulted in a 2000-fold reduction in the
infectivity of the viruses (results not shown). Groups of six mice
were inoculated s.c. with 2×106 PFU (doses of UV-treated
viruses were based on titers prior to UV treatment) of lysate or
cell-free d106-LacZ or cell-free wt HSV-1 virus at 0 and 3
weeks. Serum samples were collected from each mouse prior to
infection (week 0) and at 3 and 5 weeks after infection. Both β-
gal- and HSV-specific IgG antibody responses were analyzed
by ELISA. Wt virus-immunized mice showed high levels of
HSV-1 IgG at both 3 and 5 weeks (Fig. 6A). The d106-LacZ
virus-immunized mice also showed anti-HSV-1 IgG immune
responses but these responses were lower than those of WT
virus-infected mice. UV treatment caused a limited reduction in
the HSV-specific IgG response against HSV-1 in WT or d106-
LacZ immunized mice. On the other hand, UV inactivation
reduced the β-gal-specific IgG responses in d106-LacZ virus-cific for β-gal induced by HD-2 (A) and d106-LacZ (B) are shown. Groups of six
t HSV-1 or mock infected. At weeks 6, 9, and 12, all mice were inoculated with
re collected at the indicated times, and IgG was detected by ELISA. Results are
Fig. 6. Effect of UV inactivation of the recombinant viruses on IgG responses.
Groups of six mice were immunized twice with cell-free d106-LacZ, cell-
lysate d106-LacZ, or purified WT KOS1.1 virus with or without UV
irradiation (2×106 PFU prior to treatment, 1×103 PFU following treatment),
at weeks 0 and 3. Serum samples were collected from each mouse prior to
infection (week 0) and at 3 weeks and 5 weeks after infection. HSV-1-specific
(A) and β-galactosidase-specific (B) IgG antibody titers were determined by
ELISA, and results are shown as the mean reciprocal dilution (log2)±standard
deviation.
Fig. 7. Detection of IFN-γ-producing cells by ELISPOTassay. Groups of fifteen
mice were immunized with 2×106 PFU of cell-free d106-LacZ or HD-2 at days
0, 14, and 42. At days 3, 7, 14, 21, and 63, splenocytes were collected from each
recombinant-infected mice (three mice per group per time point) and were
stimulated with an MHC-class I (H-2Kb)-specific peptide for HSV-1 gB (A) or
β-galactosidase (B). Results are shown as the mean number of spot forming
cells (SFC)/106 splenocytes±standard deviation.
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β-galactosidase in infected mice was necessary for generation
of robust β-gal-specific IgG responses.
CD8+ T cell responses to HSV gB and β-gal epitopes
To measure the CD8+ T cell responses induced by d106-
LacZ virus immunization, we performed ELISPOT assays to
detect HSV-1 glycoprotein B- (gB-1) or β-gal-specific CD8+ T
cell responses. Groups of fifteen C57BL/6 mice were
immunized by s.c. inoculation with 2×106 PFU of either cell-
free d106-LacZ or HD-2 virus or mock infected. Booster
immunizations were performed at days 14 and 42. ELISPOT
assays were performed on splenocytes from mice at days 3, 7,
14, 21, and 63 (three mice per group per time point). HD-2 virus
elicited a strong cellular response to gB-1 (Fig. 7A) at 7 days
with a response of 1200 spot-forming cells (SFC) per 106
splenocytes. By day 63, the response had leveled off at 300–400
IFNγ SFC per 106 splenocytes (Fig. 7A). In contrast,
recombinant d106-LacZ virus induced only a weak T cell
response specific for the gB-1 epitope (Fig. 7A) consistent withits low level of viral protein expression. β-gal-specific cellular
immune responses induced by d106-LacZ virus were observed
by 7 days and continued to increase through at least 20 weeks to
400 SFC/106 splenocytes (Fig. 7B). HD-2 also elicited cellular
immunity to β-gal, but the numbers of SFC by HD-2 were
lower than those by d106-LacZ throughout the study (Fig. 7B).
Therefore, d106-LacZ virus induced specific cellular immune
responses against the transgene, β-galactosidase, without
inducing significant HSV-1 gB-specific CD8+ T cell immune
responses.
Construction of d106 vectors expressing simian
immunodeficiency virus proteins
The studies described above indicated that d106 is a good
candidate for recombinant vaccine vector. As the first step in the
application of d106 to viral vaccine vectors, we constructed
d106-based recombinants expressing SIV gag, env, and rev-
tat-nef (RTN) fusion proteins (Fig. 8A) for further studies in
nonhuman primates. We inserted RNA-optimized ORFs
encoding SIV p55 gag protein (Rosati et al., 2005) and SIV
env gp160 protein (Von Gegerfelt and Felber, 1997) into
pCIΔAflII expression vectors (Murphy et al., 2000) and
demonstrated that the cassettes expressed the appropriate
Fig. 8. Properties of d106 recombinants expressing SIV proteins. (A) Genomic maps of d106 recombinants. SIV coding sequences were inserted into the UL54 gene in
each recombinant by homologous recombination. CMV, promoter/enhancer sequences of the CMV IE gene; PA, polyadenylation signal. (B) Expression of SIV
proteins was detected by western blotting. Vero cells were infected with the indicated viruses or mock infected. Cells were harvested at indicated times, and lysates
were resolved by SDS–PAGE. SIV proteins were detected following incubation with specific monoclonal antibodies described in the text. (C) Localization of SIV gag
and env protein in cells infected with the d106 vectors. Vero cells were infected with d106-SIV.gag or d106-SIV.env, fixed with 2% formaldehyde, permeabilized with
cold acetone at 22 hpi, and stained with specific monoclonal antibodies against gag or env.
Fig. 9. Kinetics of SIV env protein expression in recombinant virus-infected
cells. Vero cells were infected with d106-SIV.env or d81 (MOI=1) and
harvested at the indicated times. Env was detected by western blotting.
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nefΔ fusion protein expression cassette as described in
Materials and methods. The expression cassettes were inserted
into the pPs27pd1 transfer plasmid (Rice et al., 1989) and then
introduced into the UL54 locus in the d106 genome by
homologous recombination as described in Materials and
methods. SIV protein expression by these three recombinants
was analyzed by western blots (Fig. 8B). Vero cells were mock-
infected or infected with d106-SIV.gag, d106-SIV.env, or
d106-SIV.RTN. Proteins in the cell lysates were resolved by
SDS–PAGE, and blots were probed with anti-gag, anti-gp120,
or anti-Nef monoclonal antibody (Fig. 8B). SIV gag expression
was detected by 6 hpi, peaked at 12 hpi, and was maintained in
the cells through at least 48 hpi. SIV env expression was
detected by 6 hpi and increased through 48 hpi. The rev-tat- nef
fusion protein was expressed by 6 hpi, also peaked at 24hpi and
was maintained through at least 48 hpi. Thus, d106 virus
recombinants were capable of long-term expression of these
SIV proteins.
Immunofluorescence studies were conducted to determine
the intracellular location of env and gag in cells infected with
these two d106 vectors. In d106-SIV.gag-infected cells, gag
was distributed throughout the cytoplasm (Fig. 8C). In cells
infected with d106-SIV.env, reticular staining characteristic ofthe ER and bright perinuclear fluorescent staining consistent
with localization of env in the Golgi apparatus was observed
(Fig. 8C).
Finally, the kinetics of SIV env gene expression was
examined in cells infected with two HSV-1 replication-defective
mutant vectors, d106-SIV.env and d81 (HSV-1 ICP27 gene
deletion mutant vector) (Murphy et al., 2000). Env protein was
expressed at higher levels in d106-SIV.env-infected cells and
increased through at least 48 hpi (Fig. 9). Env was expressed at
lower levels in d81-infected cells and peaked at 24 hpi and then
decreased by 48 hpi in these cells. Therefore, d106 gives high
levels of transgene expression that are maintained through at
least 48 hpi.
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There continues to be a dire need for novel vaccine
approaches, especially for use as AIDS vaccines. In this
study, we have examined the vaccine vector properties of an
HSV-1 viral strain that has four of its five immediate-early
genes inactivated by mutations. We previously used a
replication-defective strain that was deleted for the IE ICP27
gene as part of a study that showed partial protection against
mucosal challenge of rhesus macaques with the pathogenic
SIVmac239 virus (Murphy et al., 2000). Here we studied an
HSV-1 strain, d106 with additional IE gene mutations
(Samaniego et al., 1998), as a second-generation vaccine
vector. We observed that d106 shows many of the properties
desirable in a vaccine vector: limited cytopathogenicity, high
level expression of transgenes, ability to induce durable
immune responses, and an ability to transduce dendritic cells
and induce their maturation to lymph nodes.
Limited viral gene expression and cytopathogenicity
The enhanced immunogenicity of the transgene product
expressed by d106 as compared with other HSV-1 replication-
defective mutant strains is likely to be, at least in part, due to the
fact that d106 expresses only two HSV proteins, the IE ICP0
and early (E) ICP6 protein, the large subunit of the viral
ribonucleotide reductase. Mutational inactivation knocks out
expression of four IE proteins, ICP4, ICP27, ICP22, and ICP47.
ICP4, ICP27, and ICP22 are all required for viral gene
expression (Roizman and Knipe, 2001). Thus, there is limited
HSV gene expression and competition for antigenic presenta-
tion and immune responses. In addition, the limited gene
expression means that there is little cytopathogenicity due to
effects of newly expressed viral gene products. HSV-1 ICP4 and
ICP27 are required for inhibition of cellular transcription
(Spencer et al., 1997) and ICP27 is required for inhibition of
RNA splicing (Sandri-Goldin, 1998). ICP27 is also needed,
with vhs, to shut off host protein synthesis, likely because of its
effects on host transcription and RNA splicing but potentially
because of a direct effect on translation (Ellison et al., 2005;
Fontaine-Rodriguez et al., 2004). The lack of host shutoff and
limited cytopathogenicity allow the d106-infected cells to
remain viable and express the transgene for at least a few days.
This is also reflected in increased dendritic cell maturation and
migration to lymph nodes following infection.
Reduced immune evasion
Inhibition of host gene expression downregulates the
expression of MHC class I on HSV-infected cells (Salio et al.,
1999; Walev et al., 1992). Thus, the inactivation of ICP4 and
ICP27 will prevent this immune evasion effect induced by viral
infection. In addition, HSV ICP47 blocks peptide transport into
the endoplasmic reticulum (York et al., 1994). Therefore,
mutational inactivation of the ICP47 gene should enhance the
presentation of MHC I epitopes in d106 virus-infected cells.
Finally, ICP22 has been reported to inhibit MHC class IIpresentation (Barcy and Corey, 2001), and inactivation of the
ICP22 gene should prevent this immune evasion effect of HSV.
Efficacy in HSV-immune animals
As we observed for other replication-defective mutant
viruses (Brockman and Knipe, 2002), and others observed
for amplicon vectors (Hocknell et al., 2002), d106 is capable
of inducing normal antibody responses in HSV-immune
mice. Others have reported that HSV immunity significantly
reduces immune responses to the transgene expressed by an
HSV-1 replication-defective mutant virus (Lauterbach et al.,
2005); thus, there are differences in experimental systems or
viral vector strains and further studies of this property are
warranted.
Role of ICP0 in stimulating transgene expression
Although ICP0 is needed to stimulate transgene expression
from the HSV-1 genome (Samaniego et al., 1998), ICP0 has
also been shown to block several aspects of the host immune
response, including type I interferon induction (Lin et al., 2004;
Melroe et al., 2004). Thus, an improved vector might encode an
ICP0 molecule that can activate transgene expression without
blocking the host immune response, if these activities of ICP0
can be separated.
Amplicon vectors
An additional approach that shares some of the advantages of
the multiple IE gene deletion mutant is the amplicon vector,
which contains a DNA replication origin, packaging signals,
and the transgene of interest. In cells where helper functions are
provided by a helper virus or plasmids, the amplicon plasmid is
packaged as genome length (152 kbp) concatamers, allowing
for high levels of transgene expression in transduced cells
(Geller and Breakefield, 1988; Spaete and Frenkel, 1982). HSV-
derived amplicon systems have been produced for use as
vaccine vectors. In one system cells are cotransfected with a
BAC containing a packaging signal-deleted HSV genome,
needed to create the HSV delivery vehicle, and an HSV
amplicon plasmid, containing the HSV packaging signal and the
transgene of interest (Suter et al., 1999). The resulting amplicon
virus is devoid of any HSV DNA with the exception of the
packaging signal. HSV amplicons expressing HIV gp120 are
highly immunogenic in mice (Hocknell et al., 2002) and show
some protection of hu/SCID mice challenged with HIV
(Gorantla et al., 2005). Thus far, titers of these amplicon
vectors seem to be limiting for vaccine production.
In conclusion, this study indicates that a multiple IE gene-
deleted, replication defective HSV-1 recombinant, d106, can
effectively express foreign genes and induce strong cellular and
humoral responses in mice, raising its potential for use as a
vaccine vector in primate studies. Ongoing research involves
the studies of these vectors in nonhuman primates (Kaur et al.,
2007 (companion paper)) and studies to further optimize the
d106 virus for transgene expression and immunogenicity.
Table 1
Primer pairs used in this study
1A: 5′ GGA CGA ATT CAT GCA TTA GTT ATT AAT AGT
NoflagCMV: 5′ CGC GGATCC GCC ACC GCG GTG GAG CTC
Kozak Rev: 5′ GAC GGATCC GCC ACC ATG AGC AAT CAC GAA AG
1B: 5′ GCC GAA GCT TGT CCT GAG GAC TTC TCG AAT
2A: 5′ GGA CAA GCT TAT GGA GAC ACC CTT GAG GGA
2B: 5′ CCG TGT CGA CTC TGC CAA GGC CAG GAG CTG
3A: 5′ GGA CGT CGA CAT GGG TGG AGC TAT TTC CAT
RTN3C: 5′ CCT GCC TAG GTC AGC GAG TTT CCT TCT TGT
4A: 5′ GGA CCC TAG GCA CTC GAT CGC CCT TCC CAA
4B: 5′ CCT GGA ATT CTG CAG TGA AAA AAATGC TTT
UL48F1 5′ TATCCAGAGCGCCGTAGGGG 3′
UL48B1 5′ CTCCCACCCTGCATGGCAAC 3′
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Cells and viruses
Vero, V8-27 cells containing the HSV-1 ICP8 (UL29) and
ICP27 (UL54) genes (Da Costa et al., 2000), and E11 cells
containing the HSV-1 ICP4 and ICP27 genes (Samaniego et
al., 1998) were cultured as described. The HSV-1 d106 mutant
virus (Samaniego et al., 1998) is derived from the wild-type (wt)
strain KOS. The HSV-1 d81 replication-defective recombinant
expressing SIV env was described previously (Murphy et al.,
2000). Each recombinant was grown and assayed for infectivity
[plaque forming units (PFU)/ml] in the appropriate comple-
menting cell lines (V8-27 and E11) as described (Brockman and
Knipe, 2002). Stocks of the viruses (stocks as infected-cell
lysates or cell-free virus stocks) were generated as described
previously (Da Costa et al., 2000).
Plasmids
The transfer plasmids used in this study are derived from
plasmid pPs27pd1, which has a 6.1-kilobase pair (kbp) insert of
the HSV-1 genome that contains the entire ICP27 (UL54) gene
and flanking sequences (Rice et al., 1989). Plasmid p27-lacZ1
has an ICP27 gene deletion and a lacZ expression cassette
insertion (Rice and Knipe, 1990). The modified simian
immunodeficiency virus (SIV) gag (pCMVSgag55) and env
expression plasmids were described previously (Rosati et al.,
2005). To express the rev, tat, and nef proteins, the rev and tat
ORFs were fused to a mutated form of the nef gene that is
unable to down-regulate MHC (Murphy et al., 2000), as
described below. Expression cassettes containing the SIV ORFs
downstream from the human cytomegalovirus immediate-early
(CMV IE) promoter were constructed as described previously
(Murphy et al., 2000), and inserted into pds27pd1.
Construction of the SIV rev-tat-nef fusion protein expression
cassette (RTN)
The major immediate-early promoter/enhancer of human
cytomegalovirus virus (HCMV) was PCR-amplified from the
pCMV-revFLAG plasmid using primers 1A and NoflagCMV
(Table 1), which contain EcoRI and BamHI sites flanking the
HCMV sequence. The open reading frame for SIV rev was
PCR-amplified from a pCMV-revFLAG plasmid (rev sequence
originally from pgREVS (Malim et al., 1989) and cloned into
pCMVTag2B) using primers KozakRev and 1B, which include
BamHI and HindIII sites added to the 5′ and 3′ ends of rev
sequence and ligated to human CMV to generate a 1060 bp
fragment, CMV-rev. The tat open reading frame was PCR-
amplified from the SIV tat clone (Malim et al., 1989) using
primers 2A and 2B, which include HindIII and SalI restriction
sites added to the 5′ and 3′ ends of tat sequence, respectively,
generating a 413-bp fragment. The nef delta 239–240 reading
frame (deleted for codons 239 and 240 so that the protein does
not down-regulate MHC class I) was PCR-amplified from
plasmid pnef-delta 239–240 (Swigut et al., 2004) using primers3A and RTN3C (Table 1), which include restriction sites for SalI
and AvrII, generating an 800-bp fragment. An SV40 polyadeny-
lation signal sequence was PCR-amplified from plasmid
prevFLAG, using primers 4A and 4B (Table 1), which include
restriction sites for AvrII and EcoRI added to the ends of the
SV40 polyA sequence, to generate a 370-bp fragment. The
individual PCR fragments were ligated together to generate the
rev-tat-nef (RTN) fusion cassette of size 2643 bp:
EcoRI-CMV-rev-HindIII-tat-SalI-nef-AvrII-SV40polyA-
EcoRI
1060 bp–413 bp–800 bp–370 bp
The RTN cassette with EcoRI ends was cloned into the unique
EcoRI site of plasmid p6.3TKdeltaKpn (Murphy et al., 2000) to
generate pTK-RTN, with the coding sequence for the fusion
protein in the opposite orientation of the HSV-1 TK sequence.
The plasmid was transfected into human 293 cells and lysates
were analyzed by western blotting with anti-nef antibody.
Transfection and recombinant virus isolation
HSV DNAwas purified from infected cell lysates by sodium
iodide gradient centrifugation (Walboomers and ter Schegget,
1976). Cotransfection of the infectious viral DNA and plasmid
insert DNA was performed using Lipofectamine reagent
(Invitrogen). Plaque purification of recombinant viruses with
agarose overlay medium was performed as described previously
(Rice and Knipe, 1990).
Construction of the d106-LacZ virus
A recombinant plasmid d27-LacZ was cotransfected with
infectious d106 viral DNA into E11 cells. When the progeny
viruses from this transfected culture were plated onto E11
cells in the presence of X-gal, approximately 1% of the
plaques were blue. A blue plaque was picked, and after three
rounds of purification, one of the virus clones was designated
d106-LacZ. Recombination into the UL54 locus was
confirmed by the loss of fluorescence due to replacement of
the GFP gene. The d106-LacZ virus was unable to form
plaques on Vero cells but formed plaques efficiently on E11
cells (results not shown).
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Plasmid TKΔgag was constructed by insertion of the SIV
p55 gag ORF from the RNA-optimized cassette pCMVSgag55
(Rosati et al., 2005) into the EcoRI site of p6.3TKΔKpn
(Murphy et al., 2000). Plasmid TKΔgag was restricted with
EcoRI and treated with Mung bean nuclease to drop out a
2.9 kbp CMV-SIV gag cassette. The transfer plasmid pSd27-1
plasmid DNAwas cleaved with BamHI, treated with mung bean
nuclease to remove the single stranded extensions, treated with
calf intestinal phosphatase, and ligated to the SIV gag cassette.
The resulting plasmid was linearized and cotransfected with
d106 viral DNA into E-11 cells. Viral recombinants were
identified in a screen for non-fluorescent plaques because
homologous recombination leading to the incorporation of the
cassettes in the ICP27/UL54 locus replaces the GFP expression
cassette.
Construction of the d106-SIV.env recombinant virus
Plasmid TKΔenv was constructed by insertion of the SIV
gp160 env ORF from the RNA-optimized construct
pCMBkanR-SenvCTE (Von Gegerfelt and Felber, 1997) into
the EcoRI site of p6.3TKΔKpn (Murphy et al., 2000). TKΔenv
was restricted with EcoRI and treated with mung bean nuclease
to drop out a 4.4-kbp CMV-SIV env cassette. The transfer
plasmid pSd27-1 plasmid DNA was cleaved with BamHI,
treated with mung bean nuclease to remove the single stranded
extensions, treated with calf intestinal phosphatase, and ligated
to the SIV env cassette. The resulting plasmid was linearized
and cotransfected with d106 viral DNA into E-11 cells. Viral
recombinants were identified in a screen for non-fluorescent
plaques because homologous recombination leading to the
incorporation of the cassette in the ICP27/UL54 locus replaces
the GFP expression cassette.
Construction of the d106-SIV.RTN recombinant virus
Plasmid pTK-RTN, constructed as described above, was
restricted with EcoRI and treated with mung bean nuclease to
drop out a 4.4 kbp CMV-SIV rev-tat-nef (RTN) cassette. The
transfer plasmid pSd27-1 plasmid DNA was restricted with
BamHI, treated with mung bean nuclease to remove the single
stranded extensions, treated with calf intestinal phosphatase,
and ligated to the SIV rev-tat-nef cassette. The resulting
plasmid was linearized and cotransfected with d106 viral
DNA into E-11 cells. Viral recombinants were identified in a
screen for non-fluorescent plaques because homologous
recombination leading to the incorporation of the cassette in
the ICP27/UL54 locus replaces the GFP expression cassette.
Analysis of viral proteins
Infected cell proteins were radiolabeled by incubating
approximately 6×105 cells with 37.5 μCi of [35S]-methionine
per ml of methionine-free medium for 30 min at the indicated
time points. The labeled viral proteins were resolved by SDS–polyacrylamide gel electrophoresis (SDS–PAGE) as previously
described (Knipe and Spang, 1982). For western blot analysis of
β-galactosidase and SIV proteins, proteins were separated by
SDS–PAGE, electroblotted to nitrocellulose, and analyzed
using indicated primary antibodies and a chemiluminescence
western blotting kit (Boehringer Mannheim).
Monoclonal antibodies
The monoclonal antibodies used in this study were as
follows; anti-β-galactosidase mouse monoclonal antibody
(Promega); anti-SIV mac251 gp120 antibody (KK65), Nef
antibody (17.2) and gag antibody (KK64). The antibodies
against SIV proteins were obtained from the NIH AIDS
Research and Reference Reagent Program.
Immunofluorescence
Indirect immunofluorescence was performed as described
previously (Quinlan et al., 1984). In brief, Vero cells were
grown on coverslips and infected. At the indicated times, the
cells were fixed in cold acetone and reacted with indicated
primary antibody, washed with PBS and then reacted with
FITC-conjugated goat anti-rabbit immunoglobulin. Fluores-
cence images were viewed with an Axioplan 2 (Zeiss)
microscope equipped with an Orea cooled CCD camera
(Hamamatsu Photonics). A Zeiss 63X plan Apochromat
objective was used. Images were collected with the OpenLab
software package (Improvision). GFP expression was visua-
lized directly after fixation of infected cells.
β-Galactosidase enzyme assays
Vero cells were infected with d106-LacZ or HD-2 at MOI=1.
At various times post infection, cells were lysed in reporter lysis
buffer and incubated in assay buffer containing o-nitrophenyl1-β-
D-galactopyranoside (ONPG). β-Galactosidase enzymatic activ-
ities in cell lysates were determined using an enzyme assay system
(Promega, Madison, Wis.) according to the manufacturer's
recommendations. Protein concentrations were calculated by
comparison to a standard curve of freshly prepared β-galactosi-
dase protein (Sigma) on the basis of absorbance at 410 nm.
Protein concentrations were calculated based on the basis of
OD410.
UV inactivation of viruses
Viruses were partially inactivated by exposure to 254-nm
UV light for 10 min at a distance of 5 cm as described
previously (Morrison and Knipe, 1994). Subsequent plaque
titrations revealed that UV treatment reduced viral infectivity by
approximately 2,000-fold.
Mice and inoculations
Animal studies were conducted in accordance with National
Institutes of Health (NIH) and Harvard University guidelines.
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purchased from Jackson Laboratories (Bar Harbor, Maine)
and acclimated for 1 week prior to use. The mice were
inoculated s.c. in the left flank with 2×106 PFU of viruses, or
mock-infected by s.c. inoculation with uninfected Vero cell
lysate, followed by one or more booster inoculations at 2- or 3-
week intervals. Inoculations consisted of virus stock diluted
into a volume of 20 μl of sterile, endotoxin-free 0.9% sodium
chloride solution (Sigma), per mouse. In some cases, mice
were pre-immunized with 2×106 PFU of WT KOS1.1 virus
once or twice by subcutaneous (s.c.) inoculation into the rear
flank.
PCR detection of HSV DNA in lymph node tissue
After inoculation, both inguinal lymph nodes (LNs) of mice
were removed at the indicated times. LNs were lysed into
150 mg/ml of proteinase K and DNAwas extracted by phenol/
chloroform extraction. A part of HSV-1 UL48 coding sequence
(nucs. 103672-104116, 444 bp) was amplified by PCR from
50 ng of extracted DNA per reaction, using UL48F1 (Table 1)
as the forward primer and UL48B1 (Table 1) as the reverse
primer. The amplification consisted of an initial 5-min
denaturation step at 94 °C followed by 35 cycles of denaturation
(94 °C, 30 s)–annealing (60 °C, 30 s)–extension (72 °C, 30 s)
and a final extension at 72 °C for 5 min.
Serum collection and ELISA
Blood samples were collected by retro-orbital plexus
puncture, and sera were prepared using Becton Dickinson
Microtainer serum separators (VWR) and then stored at −20 °C
prior to analysis. Enzyme-linked immunosorbent assays
(ELISAs) to determine antigen-specific IgG titers were
conducted as described previously (Da Costa et al., 1999).
Briefly, 96-well Nunc Maxisorp microtiter plates (VWR) were
coated with HSV-1 virions (Advanced Biotechnologies Inc.) at
50 ng per well or with β-galactosidase (Sigma) at 250 ng per
well in 50 μl of sodium bicarbonate buffer (pH 9.6) (Sigma)
overnight at 4 °C. Plates were blocked with phosphate-buffered
saline (PBS, pH 7.4) containing 5% (wt/vol) nonfat milk for 1 h
at 37 °C and washed with PBS containing 0.05% Tween 20
(PBS/T) using a Skatron CellWasher 600 (Molecular Devices).
Serial two-fold dilutions of mouse sera (from 1:100 to 1:12,800)
in PBS/Twere added and incubated for 2 h at 37 °C. Following
serum antibody binding, plates were washed with PBS/T and
then incubated with a rabbit anti-mouse IgG secondary antibody
conjugated to alkaline phosphatase (1:1000 dilution; Sigma) for
1 h at 37 °C. Plates were washed with PBS/T and developed by
incubation with the alkaline phosphatase substrate p-nitrophe-
nyl phosphate (Sigma) for 20 min at room temperature, and
results were read at 405 nm on a VersaMax microplate reader
(Molecular Devices).
The IgG antibody titer was calculated as the mean reciprocal
log2 value of the last dilution resulting in an optical density
(OD) reading 0.2 units above that of a control serum
(background) (Brockman and Knipe, 2002). In each case,negative OD readings at the 1:100 dilutions were scored as
positive at a 1:50 dilution (reciprocal dilution 50= log25.65),
and this value (5.65) was used as the limit of detection and
subtracted from all results.
ELISPOT assay
To measure CD8+ T cell responses specific for HSV
glycoprotein B or β-galactosidase, an ELISPOT assay was
performed using a BD ELISPOT Set (BD Biosiences
Pharmingen). Purified anti-IFN-γ monoclonal antibody was
used to coat 96-well ELISPOT plates at 5 μg/ml in PBS at 4 °C
overnight. After washing with 0.05% Tween-20 in PBS
(PBST), 200 μl of 10% FCS in DMEM was added to each
well for 2 h at 37 °C to block non-specific binding. Freshly
prepared splenocytes diluted to 1×105 or 2×104 cells in
100 μl of DMEM with MHC class I-restricted peptides at
10 μg/ml were placed in each well and incubated at 37 °C
for 24 h. Two peptides were used in this assay; MHC class-I
restricted β-gal peptide (DAPIYTNV) or MHC class I-
restricted HSV-1 gB (SSIEFARL). Cells treated under the
same condition but incubated without peptides were used as
a negative control. PMA (50 ng/ml; Sigma) and Ionomycin
(1 μg/ml; Sigma) were added to the positive control well.
The plates were washed with PBST and incubated for 2 h at
RT with 2 μg/ml of biotinylated anti-mouse IFN-γ in each
well. The plates were then washed and treated with avidin-
HRP at 1:100 dilution for 1 h at RT. After extensive
washing, AEC Substrate Reagent (BD Biosciences) was
added to develop spots in the plates for 20 min. The plates
were rinsed and air-dried before spots were counted using a
dissecting microscope.
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